ArticleThe oncologist2016
Value: The Next Frontier in Cancer Care.
Article in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks.Frontiers in pharmacology · 2023Article
- Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer.International journal of particle therapy · 2021Article
- Personalized Clinical Research: Childhood Cancer Survivor and Parent Preferences for Research Participation.JCO oncology practice · 2020Article
- Adverse events in deceased hospitalised cancer patients as a measure of quality and safety in end-of-life cancer care.BMC palliative care · 2020Article
- Unwarranted imaging for distant metastases in patients with newly diagnosed ductal carcinoma in situ and stage I and II breast cancerCanadian journal of surgery. Journal canadien de chirurgie · 2020Article
- Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.Journal of managed care & specialty pharmacy · 2019Review
- Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System.Applied health economics and health policy · 2019Article
- This is a call to oncologists for action.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Early Steps in the Value of Cancer Care-Many Paths Remain Unexplored.The oncologist · 2018Article
- Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies".The oncologist · 2017Article
- Choosing wisely in cancer control across Canada-a set of baseline indicators.Current oncology (Toronto, Ont.) · 2017Article
- Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.Journal of managed care & specialty pharmacy · 2017Article
- AMCP Partnership Forum: Driving Value and Outcomes in Oncology.Journal of managed care & specialty pharmacy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.